UPDATE: JP Morgan Upgrades Teva Pharmaceuticals

Loading...
Loading...
On Friday, JP Morgan upgraded shares of
Teva PharmaceuticalsTEVA
from Underweight to Neutral and raised the profit target to $49. Analyst Chris Schott is encouraged by “favorable initial Copaxone 3x weekly trends and the potential for additional cost cutting activity,” but remains “less enthusiastic around Teva's organic growth prospects and its P&L reliance on Copaxone.” Schott expects Teva management's “willingness to consider larger business development opportunities will be well received.” Shares of Teva are up 21 percent year-to-date and up 1.8 percent to $48.82 during Friday's session.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorAnalyst RatingsChris SchottJP Morgan
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...